MedTrace Logo

Asia Pacific and Russia Diagnostic Study for EGFR Testing

NCT01788163 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3500

Last updated 2017-05-17

Study results available
· View outcomes & findings →

Summary

Interventional diagnostic, international, multicenter and non-comparative study of EGFR mutation status in aNSCLC patients (locally advanced and/or metastatic disease) with adenocarcinoma and non-adenocarcinoma histologies. It will be conducted in Asia Pacific and Russia and will assess the current status of EGFR mutation testing, and the concordance of EGFR mutation status derived from tumour samples and blood based circulating free DNA.

Conditions

  • EGFR Mutation Status in aNSCLC Patients

Interventions

GENETIC

EGFR mutation test

EGFR mutation being tested in tissue and blood

Sponsors & Collaborators

Principal Investigators

  • Rose McCormack, PhD · AstraZeneca, PHB

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-02-27
Primary Completion
2014-08-25
Completion
2016-06-20

Countries

  • Australia
  • China
  • Indonesia
  • Malaysia
  • Russia
  • Singapore
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01788163 on ClinicalTrials.gov